CRBN Antibody

Code CSB-PA842761ESR2HU
Size US$299Purchase it in Cusabio online store
(only available for customers from the US)
Image
  • Western blot
    All lanes: CRBN antibody at 5.28µg/ml
    Lane 1: Mouse liver tissue
    Lane 2: A375 whole cell lysate
    Secondary
    Goat polyclonal to rabbit IgG at 1/10000 dilution
    Predicted band size: 51 kDa
    Observed band size: 51 kDa

  • Immunohistochemistry of paraffin-embedded human thyroid tissue using CSB-PA842761ESR2HU at dilution of 1:100

  • Immunohistochemistry of paraffin-embedded human heart tissue using CSB-PA842761ESR2HU at dilution of 1:100

Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name Rabbit anti-Homo sapiens (Human) CRBN Polyclonal antibody
Uniprot No. Q96SW2
Target Names CRBN
Alternative Names CRBN; AD-006; Protein cereblon
Raised in Rabbit
Species Reactivity Human, Mouse
Immunogen Recombinant Human Protein cereblon protein (1-280AA)
Immunogen Species Homo sapiens (Human)
Conjugate Non-conjugated
Clonality Polyclonal
Isotype IgG
Purification Method Antigen Affinity Purified
Concentration It differs from different batches. Please contact us to confirm it.
Buffer PBS with 0.02% sodium azide, 50% glycerol, pH7.3.
Form Liquid
Tested Applications ELISA, WB, IHC
Recommended Dilution
Application Recommended Dilution
WB 1:1000-1:5000
IHC 1:20-1:200
Protocols ELISA Protocol
Western Blotting(WB) Protocol
Immunohistochemistry (IHC) Protocol
Troubleshooting and FAQs Antibody FAQs
Storage Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Substrate recognition component of a DCX (DDB1-CUL4-X-box) E3 protein ligase complex that mediates the ubiquitination and subsequent proteasomal degradation of target proteins, such as MEIS2 (Probable). Normal degradation of key regulatory proteins is required for normal limb outgrowth and expression of the fibroblast growth factor FGF8. Maintains presynaptic glutamate release and consequently cognitive functions, such as memory and learning, by negatively regulating large-conductance calcium-activated potassium (BK) channels in excitatory neurons. Likely to function by regulating the assembly and neuronal surface expression of BK channels via its interaction with KCNT1. May also be involved in regulating anxiety-like behaviors via a BK channel-independent mechanism.
Gene References into Functions
  1. mitochondrially expressed CRBN exhibited protease activity, and was induced by oxidative stress. PMID: 27417535
  2. We sequenced CRBN-thalidomide binding region in 38 thalidomide embryopathy individuals and 136 Brazilians without congenital anomalies, and performed in silico analyses. Eight variants were identified, seven intronic and one in 3'UTR. PMID: 27751757
  3. These findings thus contribute to a growing list of ID disorders caused by CRBN mutations, broaden the spectrum of phenotypes attributable to Autosomal-recessive non-syndromic intellectual disability (ARNS-ID)and provide new insight into genotype-phenotype correlations between CRBN mutations and the aetiology of ARNS-ID. PMID: 28143899
  4. CRBN expression is of prognostic value in MM patients ineligible for ASCT treated with thalidomide as an immunomodulatory drug. With low expression indicating a possible suboptimal treatment outcome, measurement of CRBN expression might serve as additional prognostic tool in the personalized treatment approach. PMID: 27618360
  5. Plasmablast differentiation, whether induced by BAFF or CD40L, is prevented by modulation of CRBN activity with CC-220, which induces degradation of the B cell differentiation factors Aiolos and Ikaros. Downregulation of these B cell differentiation processes by CC-220 modulation of CRBN provides a new therapeutic approach to treating B cell-mediated pathology in SLE. PMID: 28848067
  6. High CRBN expression is associated with multiple myeloma. PMID: 28017969
  7. CRBN negatively regulates TLR4 signaling via attenuation of TRAF6 and TAB2 ubiquitination. PMID: 27468689
  8. Compared with newly diagnosed multiple myeloma, an increased prevalence of mutations in the Ras pathway genes KRAS, NRAS, and/or BRAF (72%), as well as TP53 (26%), CRBN (12%), and CRBN pathway genes (10%) was observed. PMID: 27458004
  9. dual assay demonstrated superior Cereblon IHC measurement in MM samples compared with the single IHC assay using a published commercial rabbit polyclonal Cereblon antibody and could be used to explore the potential utility of Cereblon as a biomarker in the clinic PMID: 26186254
  10. IRF4 and CRBN polymorphisms affect risk and response to treatment in multiple myeloma PMID: 28083618
  11. overview of the current understanding of mechanism of action of Immunomodulatory drugs via CRBN and prospects for the development of new drugs that degrade protein of interest. PMID: 27460676
  12. 45.2 of multiple myeloma patients were CRBN(+). Among patients treated with thalidomide-based regimens, CRBN(+) patients showed a better treatment response than did CRBN-negative patients. There was no significant difference in survival outcomes between thalidomide- and bortezomib-based regimens in CRBN(+) patients. PMID: 27365142
  13. GS is acetylated at lysines 11 and 14, yielding a degron that is necessary and sufficient for binding and ubiquitylation by CRL4(CRBN) and degradation by the proteasome. PMID: 26990986
  14. Structural dynamics of the cereblon ligand binding domain. PMID: 26024445
  15. Our data are consistent with the idea that the CUL4A/B-DDB1-CRBN complex catalyses the polyubiquitination and thus controls the degradation of CLC-1 channels. PMID: 26021757
  16. Data suggest that cereblon (CRBN) expression in peripheral blood chronic lymphocytic leukemia (CLL) cells is independent of prognostic factors and may be considered a potential biomarker. PMID: 24925210
  17. High levels of full-length CRBN mRNA in lower risk 5q deletion patients are necessary for the efficacy of lenalidomide. PMID: 25284710
  18. A copy number gain of CRBN gene might be responsible for developmental delay/intellectual disability. PMID: 25858704
  19. Although abnormal CRBN function may be associated with intellectual disability disease onset, its cellular mechanism is still unclear. Here, we examine the role of CRBN in aggresome formation and cytoprotection. PMID: 26188093
  20. Studied the protein cereblon , which has been recently indentified as a primary target of thalidomide and its C-terminal part as responsible for binding thalidomide within a domain carrying several invariant cysteine and tryptophan residues. PMID: 25569776
  21. The study presents the crystal structure of human CRBN bound to DDB1 and the drug lenalidomide. PMID: 25108355
  22. structures of the DDB1-CRBN complex bound to thalidomide, lenalidomide and pomalidomide PMID: 25043012
  23. CRBN expression in bone marrow myeloma cells is associated with superior treatment response to lenalidomide in refractory myeloma and thalidomide/dexamethasone in new patients. CRBN is a crucial factor for the anti-MM effect of immunomodulators. PMID: 24687382
  24. CRBN expression may provide a biomarker to predict response to Immunomodulatory drugs in patients with MM and its high expression can serve as a marker of good prognosis. PMID: 24118365
  25. CRBN and IRF4 have been shown to be associated with response to lenalidomide in patients, these findings do not translate back to HMCLs, which could be attributable to factors present in the bone marrow microenvironment. PMID: 23992230
  26. In the three intrinsically IMiD-resistant cell lines that clearly express detectable levels of cereblon, the absence of CRBN and DDB1 mutations suggest that potential cereblon-independent mechanisms of resistance exist PMID: 24166296
  27. Presents a molecular model in which drug binding to cereblon results in the interaction of Ikaros and Aiolos to CRL4(CRBN) , leading to their ubiquitination, subsequent proteasomal degradation and T cell activation. PMID: 24328678
  28. Data indicate that low cereblon (CRBN) expression can predict resistance to immunomodulatory drug (IMiD monotherapy and is a predictive biomarker for survival outcomes. PMID: 24129344
  29. Findings suggest an approach for the treatment of mental retardation associated with cereblon nonsense mutation. PMID: 23983124
  30. We investigated the role of CRBN in response to lenalidomide in myelodysplastic syndrome infants without chromosome 5 deletion. PMID: 23434730
  31. We conclude that CRBN expression may be associated with the clinical efficacy of thalidomide. PMID: 23233657
  32. These findings suggest that CRBN may modulate proteasome activity by directly interacting with the beta7 subunit. PMID: 23026050
  33. Data show that in a cereblon-dependent fashion, lenalidomide downregulates IRF4 and SPIB, transcription factors that together prevent IFNbeta production. PMID: 22698399
  34. CRBN is an essential requirement for immunoregulatory drugs activity and a possible biomarker for the clinical assessment of antimyeloma efficacy. PMID: 21860026
  35. CRBN directly interacts with the alpha1 subunit of AMP-activated protein kinase (AMPK alpha1) and inhibits the activation of AMPK activation. PMID: 21232561
  36. The results suggest that mutCRBN may cause ARNSID by disrupting the developmental regulation of BK(Ca) in brain regions that are critical for memory and learning. PMID: 20131966
  37. A nonsense mutation causing a premature stop codon in CRBN was found in a large kindred with mild mental retardation. ATP-dependent degradation of proteins may play a role in memory and learning. PMID: 15557513
  38. This may suggest new functions of CRBN in cell nucleolus besides its mitochondria protease activity in cytoplasm. PMID: 17380424
  39. Nonsense mutation (R419X) CRBN disturbs the development of adult brain BK(Ca) isoforms. These changes are predicted to result in BK(Ca) channels with a higher intracellular Ca(2+) sensitivity, faster activation, and slower deactivation kinetics. PMID: 18414909

Show More

Hide All

Involvement in disease Mental retardation, autosomal recessive 2A (MRT2A)
Subcellular Location Cytoplasm. Nucleus. Membrane; Peripheral membrane protein.
Protein Families CRBN family
Tissue Specificity Widely expressed. Highly expressed in brain.
Database Links

HGNC: 30185

OMIM: 607417

KEGG: hsa:51185

STRING: 9606.ENSP00000231948

UniGene: Hs.18925

Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
Address
7505 Fannin St. Ste 610-312, Houston, TX 77054, USA
Join Us with

Subscribe newsletter

Leave a message

© 2007-2022 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1